Ryan M. Hickey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryan M. Hickey has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Riad Salem
Department of Radiology, Section of Vascular and Interventional Radiology, Northwestern University, Chicago, USA
3 shared publications - Robert J. Lewandowski
Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
2 shared publications - Ahmed Gabr
Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA
1 shared publication - Al Bowen Benson
Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
1 shared publication Bartley G. Thornburg
Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, Illinois
1 shared publicationBartley Thornburg
Department of Radiology, Section of Interventional Radiology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St. Clair, Suite 800, Chicago, IL 60611
1 shared publication
Latest Publications
- 30 August 2016
- Published by Cambridge University Press (CUP)
- p. 128-133
90Yttrium radioembolization for hepatocellular carcinoma
Radioembolization refers to the intra-arterial, transcatheter administration of micrometer-sized particles loaded with a radioisotope, most commonly yttrium-90 (Y90). Because liver tumors derive the majority of their blood supply from hepatic arteries, as opposed to the predominantly portal venous blood supply of normal liver tissue, hepatic arterial injection of Y90-labeled microspheres results in greater deposition of the spheres in tumor tissue as opposed to normal liver parenchyma. Since Y90 radioembolization provides an internal source of radiation to hepatic tumors, it is considered brachytherapy. Preferential deposition of radioactive microspheres within tumor tissue provides for relative sparing of the uninvolved liver parenchyma from the radiation effects of Y90, thereby permitting significantly higher radiation doses than can be safely administered using external-beam radiation. The radiosensitive nature of normal liver tissue has traditionally limited the role of external-beam radiation in the treatment of primary and metastatic hepatic malignancies, as the incidence of severe radiation-induced liver disease (RILD) may exceed 50% for external-beam radiation doses greater than 35–40 Gy. However, with radioembolization, radiation doses in excess of 150 Gy can be safely administered. Y90, a pure beta emitter with a half-life of 64.2 hours and tissue penetration of 2.5–11 mm, is incorporated into glass or resin microspheres ranging in size from 20–30 μm (glass) to 20–60 μm (resin). Glass microspheres (Therasphere, BTG International Canada, Ottawa, ON, Canada) were approved in 1999 by the US Food and Drug Administration (FDA) under a Humanitarian Device Exemption for the treatment of unresectable hepatocellular carcinoma (HCC). Resin microspheres (SIR-Spheres, Sirtex Medical, Lane Cove, Australia) were granted full premarketing approval in 2002 by the US FDA for the treatment of unresectable colorectal metastases in conjunction with intrahepatic floxuridine. Safe and effective treatment of hepatic tumors with radioembolization requires not only the angiographic and endovascular skills critical for selective embolization procedures, but also a comprehensive understanding of radiation administration and safety, including radiation dosimetry and radiation dose modification based on tumor characteristics and a patient's clinical profile. Patient selection The patient selection process for Y90 radioembolization involves an assessment of the patient's burden of disease, hepatic biochemical profile, and performance status. Patients should have no extrahepatic disease and a tumor burden less than 70% of the liver volume.
- 30 August 2016
- Published by Cambridge University Press (CUP)
- p. 128-133
90Yttrium radioembolization for hepatocellular carcinoma
Radioembolization refers to the intra-arterial, transcatheter administration of micrometer-sized particles loaded with a radioisotope, most commonly yttrium-90 (Y90). Because liver tumors derive the majority of their blood supply from hepatic arteries, as opposed to the predominantly portal venous blood supply of normal liver tissue, hepatic arterial injection of Y90-labeled microspheres results in greater deposition of the spheres in tumor tissue as opposed to normal liver parenchyma. Since Y90 radioembolization provides an internal source of radiation to hepatic tumors, it is considered brachytherapy. Preferential deposition of radioactive microspheres within tumor tissue provides for relative sparing of the uninvolved liver parenchyma from the radiation effects of Y90, thereby permitting significantly higher radiation doses than can be safely administered using external-beam radiation. The radiosensitive nature of normal liver tissue has traditionally limited the role of external-beam radiation in the treatment of primary and metastatic hepatic malignancies, as the incidence of severe radiation-induced liver disease (RILD) may exceed 50% for external-beam radiation doses greater than 35–40 Gy. However, with radioembolization, radiation doses in excess of 150 Gy can be safely administered. Y90, a pure beta emitter with a half-life of 64.2 hours and tissue penetration of 2.5–11 mm, is incorporated into glass or resin microspheres ranging in size from 20–30 μm (glass) to 20–60 μm (resin). Glass microspheres (Therasphere, BTG International Canada, Ottawa, ON, Canada) were approved in 1999 by the US Food and Drug Administration (FDA) under a Humanitarian Device Exemption for the treatment of unresectable hepatocellular carcinoma (HCC). Resin microspheres (SIR-Spheres, Sirtex Medical, Lane Cove, Australia) were granted full premarketing approval in 2002 by the US FDA for the treatment of unresectable colorectal metastases in conjunction with intrahepatic floxuridine. Safe and effective treatment of hepatic tumors with radioembolization requires not only the angiographic and endovascular skills critical for selective embolization procedures, but also a comprehensive understanding of radiation administration and safety, including radiation dosimetry and radiation dose modification based on tumor characteristics and a patient's clinical profile. Patient selection The patient selection process for Y90 radioembolization involves an assessment of the patient's burden of disease, hepatic biochemical profile, and performance status. Patients should have no extrahepatic disease and a tumor burden less than 70% of the liver volume.
- 10 May 2016
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 33 (02) , 101-104
Inferior Vena Cava Filter–Related Thrombus/Deep Vein Thrombosis: Data and Management
Recurrent deep venous thrombosis and inferior vena cava (IVC) thrombosis are well-described complications following IVC filter placement. IVC thrombosis ranges in severity of clinical presentation, but can lead to significant morbidity and mortality with incidence rates depending on patient population and type of filter used. Endovascular therapies such as catheter-directed thrombolysis, mechanical thrombectomy, balloon venoplasty, and stenting are safe and effective in restoration of venous patency.
- 10 May 2016
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 33 (02) , 101-104
Inferior Vena Cava Filter–Related Thrombus/Deep Vein Thrombosis: Data and Management
Recurrent deep venous thrombosis and inferior vena cava (IVC) thrombosis are well-described complications following IVC filter placement. IVC thrombosis ranges in severity of clinical presentation, but can lead to significant morbidity and mortality with incidence rates depending on patient population and type of filter used. Endovascular therapies such as catheter-directed thrombolysis, mechanical thrombectomy, balloon venoplasty, and stenting are safe and effective in restoration of venous patency.
- 6 April 2016
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 27 (9) , 1279-1287
Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival
- 6 April 2016
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 27 (9) , 1279-1287
Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival
- Open Access
- 31 October 2014
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (3) , 706-707
Yttrium-90 Radioembolization is a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases: Further Evidence in Support of a New Treatment Paradigm
- 31 October 2014
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (3) , 706-707
Open AccessYttrium-90 Radioembolization is a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases: Further Evidence in Support of a New Treatment Paradigm
- 1 June 2014
- Published by Taylor & Francis in Hepatic Oncology
- Vol. 1 (3) , 285-291
Rationale of transcatheter intra-arterial therapies of hepatic cancers
SUMMARY: Transcatheter, intra-arterial therapies for primary and metastatic hepatic malignancies comprise angiographically guided procedures that provide for the administration of tumoricidal agents directly to liver tumors. These locoregional therapies have demonstrated encouraging clinical outcomes for liver tumors that are otherwise not amenable or not responsive to standard surgical or systemic treatments. This article provides a review of transcatheter therapies for hepatic cancers and reported clinical outcomes.
- 1 June 2014
- Published by Taylor & Francis in Hepatic Oncology
- Vol. 1 (3) , 285-291
Rationale of transcatheter intra-arterial therapies of hepatic cancers
SUMMARY: Transcatheter, intra-arterial therapies for primary and metastatic hepatic malignancies comprise angiographically guided procedures that provide for the administration of tumoricidal agents directly to liver tumors. These locoregional therapies have demonstrated encouraging clinical outcomes for liver tumors that are otherwise not amenable or not responsive to standard surgical or systemic treatments. This article provides a review of transcatheter therapies for hepatic cancers and reported clinical outcomes.